Test Details
Methodology
Immunohistochemistry (IHC)
Result Turnaround Time
5 - 9 days
Special Instructions
Note: This test number is used for tracking oncology IHC specimens to the laboratory. Bill codes will be added when testing is complete, based on the processes performed in the laboratory.
Specimen Requirements
References
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-1639.26412456
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non−small-cell lung cancer. N Engl J Med. 2015 Jul 9; 373(2):123-135.26028407
Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non−small-cell lung cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-2012.25897158
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031.31562796
Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Chicago, Ill; Annual Meeting of the American Society of Clinical Oncology; 2015. Abstract LBA109.
Sundar R, Cho BC, Brahmer JR, Soo R. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85-96.25755681
Specimen
Tissue
Volume
One formalin-fixed paraffin-embedded (FFPE) tissue block or five unstained positively charged slides sectioned from FFPE tissue block at 4 to 5 microns.
Minimum Volume
Three unstained tissue slides
Storage Instructions
Room temperature
Causes for Rejection
Insufficient tissue; tumor other than non-small-cell lung cancer
Collection Instructions
Tissue should be fixed in 10% neutral buffered formalin for no more than 72 hours. Embed in paraffin.
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 480588 | PD-L1 IHC, OPDIVO(R) | 85148-5 | 480578 | Result | 83055-4 | |
| 480588 | PD-L1 IHC, OPDIVO(R) | 85148-5 | 480579 | % Tumor Cells Staining: | % | 83053-9 |
| 480588 | PD-L1 IHC, OPDIVO(R) | 85148-5 | 480584 | Comments: | 77202-0 | |
| 480588 | PD-L1 IHC, OPDIVO(R) | 85148-5 | 480586 | Interpretation: | 77202-0 | |
| 480588 | PD-L1 IHC, OPDIVO(R) | 85148-5 | 480587 | Director Review | 72486-4 | |
| Order Code | 480588 | |||||
| Order Code Name | PD-L1 IHC, OPDIVO(R) | |||||
| Order Loinc | 85148-5 | |||||
| Result Code | 480578 | |||||
| Result Code Name | Result | |||||
| UofM | ||||||
| Result LOINC | 83055-4 | |||||
| Order Code | 480588 | |||||
| Order Code Name | PD-L1 IHC, OPDIVO(R) | |||||
| Order Loinc | 85148-5 | |||||
| Result Code | 480579 | |||||
| Result Code Name | % Tumor Cells Staining: | |||||
| UofM | % | |||||
| Result LOINC | 83053-9 | |||||
| Order Code | 480588 | |||||
| Order Code Name | PD-L1 IHC, OPDIVO(R) | |||||
| Order Loinc | 85148-5 | |||||
| Result Code | 480584 | |||||
| Result Code Name | Comments: | |||||
| UofM | ||||||
| Result LOINC | 77202-0 | |||||
| Order Code | 480588 | |||||
| Order Code Name | PD-L1 IHC, OPDIVO(R) | |||||
| Order Loinc | 85148-5 | |||||
| Result Code | 480586 | |||||
| Result Code Name | Interpretation: | |||||
| UofM | ||||||
| Result LOINC | 77202-0 | |||||
| Order Code | 480588 | |||||
| Order Code Name | PD-L1 IHC, OPDIVO(R) | |||||
| Order Loinc | 85148-5 | |||||
| Result Code | 480587 | |||||
| Result Code Name | Director Review | |||||
| UofM | ||||||
| Result LOINC | 72486-4 |